Finding common ground on how “best” to treat localized prostate cancer, and what to tell the patients

One of the hardest issues for newly diagnosed prostate cancer patients to deal with has long been the differences in opinion between physicians about appropriate first-line treatment (and the relevant information they are offered) — most especially for patients with localized disease. … READ MORE …

Clinical trial design, clinical advice to patients, and clinical decision-making: not the same thing at all

In a recent opinion piece in the Journal of Clinical Oncology, Dr. Anthony D’Amico (a prostate cancer specialist for whom we have great respect) has again aired his concerns about risk for progression to metastatic disease among men on active surveillance. … READ MORE …

“Competitive analysis” in the development of drugs for advanced prostate cancer

So the other morning your sitemaster learned that a relatively new FirstWord Therapy Report had come out that dealt with future use of biopharmaceuticals in the treatment of progressive and advanced prostate cancer. … READ MORE …

What does “value” mean for prostate cancer patients?

Many readers who weren’t able to join us on yesterday’s CureTalk panel discussion may want to listen to what was a wide-ranging discussion about things that are really valuable to prostate cancers patients at diagnosis and along their prostate cancer journey. … READ MORE …

Satisfaction with “information provision” among Dutch prostate cancer patients

Sometimes — your sitemaster is willing to admit — he can become distinctly aggravated by the quality and conclusions of certain types of research related to the management of prostate cancer. … READ MORE …

Quality of life after standard therapies for localized prostate cancer

Assessment of patient quality of life (QoL) after standard forms of treatment for localized prostate cancer is difficult for many reasons — not least because there is no real agreement among members of the research community about the best ways to measure QoL or patient satisfaction after treatment. … READ MORE …

Preliminary data from SWOG/CRAB survey on patient/survivor needs

Last October we were able to assist the Southwest Oncology Group (SWOG) and Cancer Research and Biostatistics (CRAB) by asking readers to participate in an online survey dealing with the needs of patients (“survivors”) in providing follow-up cancer information after initial treatment for their cancer. The early results are in. … READ MORE …